Aprea Therapeutics, Inc. Financials
This page shows Aprea Therapeutics, Inc. (APRE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity-funded drug development is sustaining operations as cash burn eases, but the cash cushion keeps shrinking.
In FY2025, net loss of-$12.6M and operating cash burn of-$12.9M were nearly identical, so the reported loss is translating into real cash use rather than being distorted by large non-cash items. But cash still fell to$14.6M even with financing inflows, and the doubling of shares outstanding over the last two annual periods shows the company is funding that burn mainly through equity issuance instead of debt.
The balance sheet is still liquid: cash of
The recent improvement in losses looks more like a research-spend reset than broad operating leverage. R&D fell to
Financial Health Signals
Aprea Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Aprea Therapeutics, Inc. passes 0 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Aprea Therapeutics, Inc. reported a net loss of $12.6M while operations used $12.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Aprea Therapeutics, Inc.'s EBITDA was -$13.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.6% from the prior year.
Aprea Therapeutics, Inc. reported -$12.6M in net income in fiscal year 2025. This represents an increase of 2.8% from the prior year.
Aprea Therapeutics, Inc. earned -$1.93 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Aprea Therapeutics, Inc. held $14.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Aprea Therapeutics, Inc.'s ROE was -101.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 34.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Aprea Therapeutics, Inc. invested $7.0M in research and development in fiscal year 2025. This represents a decrease of 24.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
APRE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $7.0M-24.8% | $9.4M+22.8% | $7.6M-53.5% | $16.4M-31.4% | $23.9M-36.9% | $37.9M+80.8% | $21.0M+47.6% | $14.2M+6.0% | $13.4M |
| SG&A Expenses | N/A | $6.5M+0.3% | $6.5M-23.4% | $8.4M-59.8% | $21.0M+54.8% | $13.6M-9.3% | $14.9M+73.8% | $8.6M+274.5% | $2.3M-6.7% | $2.5M |
| Operating Income | N/A | -$13.2M+7.6% | -$14.3M+7.4% | -$15.5M+86.4% | -$113.4M-202.8% | -$37.4M | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | -$12.6M+2.8% | -$13.0M+9.3% | -$14.3M+87.3% | -$112.7M-203.4% | -$37.1M+30.6% | -$53.5M-90.6% | -$28.1M-80.7% | -$15.5M-2.2% | -$15.2M |
| EPS (Diluted) | — | -$1.93 | -$2.35 | -$3.95 | -$67.99 | -$34.88+31.1% | -$50.61 | -$4.67 | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
APRE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $15.9M-33.6% | $24.0M+5.9% | $22.7M-24.9% | $30.2M-46.9% | $56.8M-38.8% | $92.8M-30.5% | $133.6M+102.4% | $66.0M | N/A |
| Current Assets | $15.6M-34.0% | $23.6M+4.7% | $22.5M-25.3% | $30.2M-46.7% | $56.6M-38.8% | $92.4M-30.5% | $133.0M+101.6% | $66.0M | N/A |
| Cash & Equivalents | $14.6M-36.1% | $22.8M+5.8% | $21.6M-24.9% | $28.8M-45.8% | $53.1M-40.4% | $89.0M-31.6% | $130.1M+98.1% | $65.7M+169.1% | $24.4M |
| Total Liabilities | $3.5M-25.3% | $4.7M-18.0% | $5.7M+78.0% | $3.2M-56.2% | $7.3M-52.5% | $15.4M+64.6% | $9.4M-92.0% | $117.5M | N/A |
| Current Liabilities | $2.8M-17.8% | $3.4M-23.4% | $4.4M+37.0% | $3.2M-56.2% | $7.3M-52.3% | $15.3M+69.2% | $9.1M+86.1% | $4.9M | N/A |
| Total Equity | $12.4M-35.6% | $19.3M+13.9% | $17.0M-33.9% | $25.6M-48.2% | $49.5M-36.0% | $77.4M-37.7% | $124.2M+341.5% | -$51.4M-43.8% | -$35.8M |
| Retained Earnings | -$333.6M-3.9% | -$321.0M-4.2% | -$308.1M-4.9% | -$293.8M-62.2% | -$181.1M-25.8% | -$144.0M-59.1% | -$90.5M-44.9% | -$62.5M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
APRE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.2M | -$12.9M+4.9% | -$13.6M-11.3% | -$12.2M+51.3% | -$25.0M+33.6% | -$37.7M+9.8% | -$41.8M-56.5% | -$26.7M-75.1% | -$15.3M-8.9% | -$14.0M |
| Capital Expenditures | N/A | N/A | $15K-83.4% | $93K | N/A | N/A | $26K-16.8% | $31K+734.7% | $4K | N/A |
| Free Cash Flow | N/A | N/A | -$13.6M-10.6% | -$12.3M | N/A | N/A | -$41.8M-56.4% | -$26.7M-75.3% | -$15.3M | N/A |
| Investing Cash Flow | N/A | N/A | -$15K+83.4% | -$93K | N/A | N/A | -$26K+16.8% | -$31K-734.7% | -$4K | N/A |
| Financing Cash Flow | $36.9M | $4.6M-68.7% | $14.8M+188.4% | $5.1M+652.6% | $683K-60.9% | $1.7M+1057.4% | $151K-99.8% | $92.6M+64.2% | $56.4M+141.5% | $23.3M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
APRE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | -101.3%-34.1pp | -67.1%+17.1pp | -84.3%+355.1pp | -439.3%-364.3pp | -75.0%-5.9pp | -69.1%-46.5pp | -22.6% | N/A | N/A |
| Return on Assets | -79.1%-25.0pp | -54.0%+9.0pp | -63.1%+310.5pp | -373.6%-308.3pp | -65.3%-7.7pp | -57.6%-36.6pp | -21.0%+2.5pp | -23.5% | N/A |
| Current Ratio | 5.63-1.4x | 7.01+1.9x | 5.14-4.3x | 9.42+1.7x | 7.73+1.7x | 6.03-8.7x | 14.68+1.1x | 13.56 | N/A |
| Debt-to-Equity | 0.280.0x | 0.24-0.1x | 0.34+0.2x | 0.120.0x | 0.15-0.1x | 0.20+0.1x | 0.08 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Aprea Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Aprea Therapeutics, Inc. profitable?
No, Aprea Therapeutics, Inc. (APRE) reported a net income of -$12.6M in fiscal year 2025.
What is Aprea Therapeutics, Inc.'s EBITDA?
Aprea Therapeutics, Inc. (APRE) had EBITDA of -$13.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aprea Therapeutics, Inc.'s return on equity (ROE)?
Aprea Therapeutics, Inc. (APRE) has a return on equity of -101.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aprea Therapeutics, Inc.'s operating cash flow?
Aprea Therapeutics, Inc. (APRE) recorded an outflow of $12.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aprea Therapeutics, Inc.'s total assets?
Aprea Therapeutics, Inc. (APRE) had $15.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Aprea Therapeutics, Inc. spend on research and development?
Aprea Therapeutics, Inc. (APRE) invested $7.0M in research and development during fiscal year 2025.
What is Aprea Therapeutics, Inc.'s current ratio?
Aprea Therapeutics, Inc. (APRE) had a current ratio of 5.63 as of fiscal year 2025, which is generally considered healthy.
What is Aprea Therapeutics, Inc.'s debt-to-equity ratio?
Aprea Therapeutics, Inc. (APRE) had a debt-to-equity ratio of 0.28 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aprea Therapeutics, Inc.'s return on assets (ROA)?
Aprea Therapeutics, Inc. (APRE) had a return on assets of -79.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Aprea Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Aprea Therapeutics, Inc. (APRE) held $14.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.9M over that year. Dividing the one by the other, the reported balance equals about 14 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Aprea Therapeutics, Inc.'s Piotroski F-Score?
Aprea Therapeutics, Inc. (APRE) has a Piotroski F-Score of 0 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aprea Therapeutics, Inc.'s earnings high quality?
Aprea Therapeutics, Inc. (APRE) reported a net loss of $12.6M while operations used $12.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.